The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes

Nucleic Acids Res. 2019 May 7;47(8):3921-3936. doi: 10.1093/nar/gkz127.

Abstract

The t(8;21) is one of the most frequent chromosomal translocations associated with acute myeloid leukemia (AML). We found that t(8;21) AML were extremely sensitive to THZ1, which triggered apoptosis after only 4 h. We used precision nuclear run-on transcription sequencing (PROseq) to define the global effects of THZ1 and other CDK inhibitors on RNA polymerase II dynamics. Inhibition of CDK7 using THZ1 caused wide-spread loss of promoter-proximal paused RNA polymerase. This loss of 5' pausing was associated with accumulation of polymerases in the body of a large number of genes. However, there were modest effects on genes regulated by 'super-enhancers'. At the 3' ends of genes, treatment with THZ1 suppressed RNA polymerase 'read through' at the end of the last exon, which resembled a phenotype associated with a mutant RNA polymerase with slower elongation rates. Consistent with this hypothesis, polyA site-sequencing (PolyA-seq) did not detect differences in poly A sites after THZ1 treatment. PROseq analysis after short treatments with THZ1 suggested that these 3' effects were due to altered CDK7 activity at the 5' end of long genes, and were likely to be due to slower rates of elongation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • 3' Flanking Region
  • 5' Flanking Region / drug effects
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation
  • Cyclic N-Oxides
  • Cyclin-Dependent Kinase 9 / antagonists & inhibitors
  • Cyclin-Dependent Kinase 9 / genetics
  • Cyclin-Dependent Kinase 9 / metabolism
  • Cyclin-Dependent Kinase-Activating Kinase
  • Cyclin-Dependent Kinases / antagonists & inhibitors
  • Cyclin-Dependent Kinases / genetics*
  • Cyclin-Dependent Kinases / metabolism
  • Flavonoids / pharmacology
  • Gene Expression Regulation, Leukemic*
  • Humans
  • Indolizines
  • Myeloid Cells / metabolism
  • Myeloid Cells / pathology
  • Phenylenediamines / pharmacology*
  • Piperazines / pharmacology
  • Piperidines / pharmacology
  • Piperidones / pharmacology
  • Protein Kinase Inhibitors / pharmacology*
  • Pyridines / pharmacology
  • Pyridinium Compounds / pharmacology
  • Pyrimidines / pharmacology*
  • Pyrroles / pharmacology
  • RNA Polymerase II / antagonists & inhibitors
  • RNA Polymerase II / genetics*
  • RNA Polymerase II / metabolism
  • Translocation, Genetic

Substances

  • Antineoplastic Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Cyclic N-Oxides
  • Flavonoids
  • Indolizines
  • PHA 767491
  • Phenylenediamines
  • Piperazines
  • Piperidines
  • Piperidones
  • Protein Kinase Inhibitors
  • Pyridines
  • Pyridinium Compounds
  • Pyrimidines
  • Pyrroles
  • THZ1 compound
  • alvocidib
  • dinaciclib
  • CDK9 protein, human
  • Cyclin-Dependent Kinase 9
  • Cyclin-Dependent Kinases
  • RNA Polymerase II
  • palbociclib
  • Cyclin-Dependent Kinase-Activating Kinase
  • CDK7 protein, human